About 400 reports

Filgrastim Sales, Price Analysis, & Sales Forecast - 2017 ##.

  • Biological Therapy
  • Biotechnology
  • Filgrastim
  • World
  • Demand
  • filgrastim
  • filgrastim

“Oncology drugs report - Neupogen and Neulasta - filgrastim franchise - 1991-2015 analysis; 2016-2021 expectations” is a comprehensive report on Neupogen and Neulasta, two market leading drugs (by 2015 sales) used in the treatment of chemotherapy-induced febrile neutropenia. These drugs, both belonging to biotech giant Amgen, fall under...

  • Biotechnology
  • United States
  • Amgen Inc.
  • Kyowa Hakko Kirin Co., Ltd.
  • Neupogen group
  • BARRIERS TO UPTAKE OF FILGRASTIM BIOSIMILARS
  • Filgrastim Biosimilars Approved in the 7MM

Biosimilars in Oncology Summary Recent trends in drug development have seen the price of new medicines continually increase, and there is a need for cheaper medicines to achieve global sustainable healthcare.Biologic drugs are some of the most expensive medicines to develop, as they are large complex...

  • Biotechnology
  • Biocon Limited
  • Mylan Inc.
  • Pfizer Inc.
  • Sandoz Inc.
  • Strength 1 Low; 5 High
  • First biosimilar approved in Americas

About Neutropenia Treatment Neutropenia is an abnormal condition, characterized by critically low levels of circulating neutrophils, a type of WBC found in the blood. These cells make up for the majority of circulating lymphocytes and help defend the body against infections by bacteria, viruses, and other pathogenic organisms....

  • Biotechnology
  • Therapy
  • Amgen Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.

ZYDUS CADILA Chapter ## Appendix: Abbreviations List of Tables Summary Table : Global Market for Biosimilars, by Type, Through 2022 Table ## : List of Biosimilars Produced in E.

  • Biopharmaceutical
  • Biosimilar
  • Biotechnology
  • Generic Drug
  • World
  • Amgen, Inc.: key facts

Amgen markets Neulasta, a pegylated protein based on the filgrastim molecule, primarily in the US and Europe.

  • Biotechnology
  • Amgen Inc.
  • Covance Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • ZARXIO: PARAMETERS TO TEST SIMILARITY
  • ZARXIO: OVERVIEW

Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through Risk Management and Quality by Design Summary Government support for biosimilars is increasing in key geographical markets, given the cost saving opportunities that these products represent for national healthcare budgets. A...

  • Biopharmaceutical
  • Biosimilar
  • Biotechnology
  • Generic Drug
  • Monoclonal Antibody
  • Amgen, Inc.: key facts

Amgen markets Neulasta, a pegylated protein based on the filgrastim molecule, primarily in the US and Europe.

  • Biotechnology
  • Amgen Inc.
  • Covance Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Cancer
  • PFIZER INC. - MAJOR BIOSIMILARS APPROVED FOR MARKETING

The biosimilars are poised to capture an unprecedented position in the biopharmaceutical industry driven by an increased extent of adoption and growing investment and deal making activity globally. The global biosimilars market is predicted to cross US$ 25 Billion mark by 2020. With the continuous increasing demand for biologics,...

  • Biopharmaceutical
  • Biosimilar
  • Biotechnology
  • Generic Drug
  • Pharmaceutical

Molecule insights: On the basis of molecule, the market has been segmented as Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, etc.

  • Biopharmaceutical
  • Biosimilar
  • Biotechnology
  • World
  • Market Size
  • BIOSIMILAR MANUFACTURERS ARE FOCUSING ON ROCHE'S AND AMGEN'S AGING BLOCKBUSTER PORTFOLIOS, WHILE DEALS BETWEEN SMALL AND BIG PHARMA REMAIN A KEY TREND IN 2017.
  • CURRENT AND FUTURE DIRECTIONS IN THE ONCOLOGY BIOSIMILAR SPACE

In the supportive care space, several filgrastim (Amgen' s Neupogen) biosimilars are already marketed in the ##MM.

  • Biotechnology
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • US Approved Biosimilars
  • 2.3 Overview of Biosimilars

Scope of the Report The report entitled “Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)”, provides an analysis of global biosimilar market in terms of value. The report also provides a brief analysis of the global biologics market by value and market share by products. Furthermore, the report also assesses...

  • Biotechnology
  • Amgen Inc.
  • Celltrion, Inc.
  • Pfizer Inc.
  • Sandoz Inc.

Global Biosimilars and Follow-On Biologics Market 2017-2027 ##.

  • Biosimilar
  • Biotechnology
  • World
  • Market Shares
  • Market Size

Charting the Global Biosimialr pipeline ##.

  • Biosimilar
  • Biotechnology
  • Therapy

There are three types of vaccines: ##.

  • Biotechnology
  • World
  • Market Size
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Biosimilars approved by PMDA in Japan
  • Assumptions

About Biosimilars Biosimilars are defined as the follow-on versions of original biological medicines. These are separately developed after the patent protecting the original product has expired. Biosimilars are intended to have the same MOA as original biological drugs and are designed to treat the same diseases as the innovator’s product....

  • Biotechnology
  • Biocon Limited
  • Hospira, Inc.
  • Sandoz Inc.
  • Teva Pharmaceuticals Ltd.
  • Filgrastim: Biosimilar Products in South Korea
  • Filgrastim: Biosimilar Products in China & Taiwan - 1/2

Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis The Competitive Intelligence report Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis describes product portfolios and...

  • Biotechnology
  • Filgrastim
  • G-CSF
  • United States
  • Amgen Inc.

You can easily book an appointment with one online.

  • Biotechnology
  • World
  • Forecast
  • Merck & Co., Inc.
  • Sanofi S.A.

Consequent to the approval of Novartis' Filgrastim biosimilar in the US-the first biosimilar to receive FDA approval-it is expected that the focus on biosimilars will increase in the country.

  • Biotechnology
  • North America
  • United States
  • World
  • Horizon Discovery
  • Amgen, Inc.: key facts

Amgen markets Neulasta, a pegylated protein based on the filgrastim molecule, primarily in the US and Europe.

  • Biotechnology
  • United States
  • Amgen Inc.
  • Baxter International Inc.
  • Biogen Idec Inc.
  • US: Q-TOF MASS SPECTROMETRY MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • 7.2 NORTH AMERICA

Q. ##.

  • Biotechnology
  • North America
  • United States
  • Agilent Technologies, Inc.
  • Shimadzu Corporation

ROS##+ cancer occurs in ##-##% of NSCLC.

  • Biotechnology
  • United States
  • Charles River Laboratories International, Inc.
  • Horizon Discovery
  • WuXi AppTec Co.
  • Biologics/biosimilars market in Japan
  • Hospira

About Oncology Biosimilars Cancer represents a huge burden on healthcare systems worldwide due to the high cost of treatment therapeutics. The patent expiry of many cancer therapeutics enables the entry of biosimilars into the market. Biosimilars are being incorporated into oncology treatment practices in the supportive care setting....

  • Biotechnology
  • Biocon Limited
  • Celltrion, Inc.
  • Hospira, Inc.
  • Sandoz Inc.
  • Geographical segmentation

In 2012, Novartis initiated Phase III studies for biosimilars such as Epoetin Alfa, Filgrastim, and Pegfilgrastim.

  • Biotechnology
  • AbbVie Inc.
  • Amgen Inc.
  • Merck & Co., Inc.
  • Novo Nordisk Group
  • FILGRASTIM
  • MARKET OPPORTUNITIES FOR INSULIN AND INSULIN ANALOGS BIOSIMILARS, ($M), 2013- 2020

Biosimilars are the officially approved versions of biopharmaceutical products that are manufactured by a different company following the patent expiry of the original product. Also known as subsequent entry biologics or follow-on biologics, biosimilar drugs are gaining popularity around the world as the development cost of biosimilars is...

  • Biotechnology
  • United States
  • Hospira, Inc.
  • Roche Group
  • Sandoz Inc.

##: Contribution of cancer and diabetes to overall mortality in emerging markets Figure ##: The second wave of follow-on biologics in BRIC-MS markets Figure ##: Leading companies in India by volume of approved/ launched follow-on biologics Figure ##: Status of biosimilar clinical trials in

  • Biopharmaceutical
  • Biosimilar
  • Biotechnology
  • BRIC
  • India
  • Untitled
  • NIH Research Festival Exhibit

FDA approval of Novartis' s biosimilar filing for its filgrastim biosimilar.

  • Biotechnology
  • Charles River Laboratories International, Inc.
  • genOway SA
  • Horizon Discovery
  • Taconic Biosciences, Inc.

(USA) ##.

  • Biopharmaceutical
  • Biotechnology
  • Erythropoietin
  • World
  • Market Shares

IN THE BIO-PRODUCTS GOT APPROVAL, DOMESTIC ONES SHARE ##% AND THE ONES ABROAD ##%.

  • Biotechnology
  • China
  • Demand
  • Market Size
  • Supply